NAPLES, Fla. — March 4, 2026 — Leads & Copy — CDT Equity Inc. (Nasdaq: CDT) is advancing initiatives to enhance shareholder value and broaden its strategic scope.
The company is actively expanding its pharmaceutical portfolio, including solid-form and cocrystal development programs, alongside licensed clinical assets AZD1656, AZD5658, and AZD5904 through its agreement with AstraZeneca. CDT is engaged in ongoing evaluation and out-licensing discussions to maximize the commercial and strategic potential of these assets.
CDT has completed its strategic acquisition of a 20% equity stake in Sarborg for an initial consideration of $115 million. The acquisition provides shareholders with direct participation in a growing agentic AI signature intelligence business with activities beyond pharmaceuticals, including bacteria and agrochemicals. The consideration was satisfied through the issuance of common stock and pre-funded warrants.
CDT believes the transaction enhances its asset position and broadens its exposure to scalable, data-driven opportunity sets across multiple industries. The company is evaluating opportunities that could transform its balance sheet and market capitalization. Strategic transactions, partnerships, and corporate initiatives are also being assessed.
Subject to customary approvals, CDT expects to retain access to capital markets tools to strengthen its financial flexibility and strategic optionality.
According to Dr. Andrew Regan, Chief Executive of CDT, the company is focused on pursuing transformational opportunities that enhance shareholder value. Regan added that through its investment in Sarborg, continued development of its pharmaceutical portfolio, and disciplined evaluation of strategic transactions, CDT has multiple pathways to drive long-term growth.
CDT continues to evaluate capital markets initiatives to further strengthen its financial flexibility and support the execution of its strategic objectives.
CDT Equity Inc. is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments and is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
Source: CDT Equity Inc.
